Patient characteristics
| Mean age, y (range) | 56 (41-77) |
| Sex | |
| Male | 21 |
| Female | 8 |
| Durie-Salmon stage | |
| IA | 1 |
| IIA | 4 |
| IIIA | 21 |
| IIIB | 3 |
| Clinical isotype | |
| IgG | 19 |
| IgA | 7 |
| IgD | 1 |
| Light chain | 2 |
| Therapy* | |
| Conventional | 12 |
| High dose | 17 |
| Mean age, y (range) | 56 (41-77) |
| Sex | |
| Male | 21 |
| Female | 8 |
| Durie-Salmon stage | |
| IA | 1 |
| IIA | 4 |
| IIIA | 21 |
| IIIB | 3 |
| Clinical isotype | |
| IgG | 19 |
| IgA | 7 |
| IgD | 1 |
| Light chain | 2 |
| Therapy* | |
| Conventional | 12 |
| High dose | 17 |
Conventional therapy refers to standard-dose chemotherapy and/or corticosteroid therapy without growth factor or stem cell support. High dose refers to high-dose melphalan with autologous stem cell support.